This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Emergent Biosolutions (EBS) closed the most recent trading day at $89.87, moving +1.01% from the previous trading session.
Emergent (EBS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Jobless Claims Rise First Time Since March: 5 Defensive Picks
by Sreoshi Bera
The spike in unemployment claims and looming coronavirus fears have made markets volatile, making defensive picks lucrative investment options.
Top Ranked Momentum Stocks to Buy for July 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 23rd.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Is Emergent Biosolutions (EBS) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.
Top Ranked Momentum Stocks to Buy for July 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 21st
Here's Why Emergent Biosolutions (EBS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Emergent Biosolutions (EBS) have what it takes to be a top stock pick for momentum investors? Let's find out.
PhaseBio Initiates Phase II Study for Coronavirus Patients
by Zacks Equity Research
PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.
AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Dynavax Signs a Pact to Develop Universal Influenza Vaccine
by Zacks Equity Research
Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
by Zacks Equity Research
AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
Tricida (TCDA) Plummets on Regulatory Update on Veverimer
by Zacks Equity Research
Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin
by Zacks Equity Research
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
by Zacks Equity Research
Zacks.com featured highlights include: Nautilus, Ameresco, Canadian Solar, Emergent BioSolutions and Pacira BioSciences
Blueprint Medicines, Roche to Develop Pralsetinib for Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) signs a contract with Roche to commercialize pralsetinib for treating patients with RET-fusion NSCLC, RET-mutant MTC, other thyroid cancers and other solid tumors.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.